Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in active psoriatic arthritis (FUTURE 1 extension)
NCT01892436Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2013
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of secukinumab in psoriatic arthritis (PsA), sponsored by Novartis. Started Sep 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT01892436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01892436.